While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

Moderna is set to receive $590m in funding from the HHS to expedite the development of mRNA-based pandemic influenza vaccines ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

Earlier this month, Moderna announced business updates and progress across its pipeline. Moderna says it enters 2025 with a ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...